Search

Your search keyword '"MELMER, ANDREAS"' showing total 165 results
Start Over Author "MELMER, ANDREAS"
165 results on '"MELMER, ANDREAS"'

1. Bariatric surgery prevents carotid wall thickness progression

Author

Lunger, Lukas, Melmer, Andreas, Sturm, Wolfgang, Lamina, Claudia, Tschoner, Alexander, Engl, Julia, Hönlinger, Armin, Engler, Clemens, Willeit, Peter, Kiechl, Stefan, Willeit, Johann, Öfner, Dietmar, Wykypiel, Heinz, Laimer, Markus, Tilg, Herbert, and Ebenbichler, Christoph

Published
2023
Full Text
View/download PDF

2. Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial

Author

Kühne, Tobias, primary, Wallace, Esmè, additional, Herzig, David, additional, Helleputte, Simon, additional, Scott, Sam, additional, Pickles, Jordan, additional, Melmer, Andreas, additional, and Stettler, Christoph, additional

Published
2024
Full Text
View/download PDF

3. Effects of home‐based exergaming on cardio‐metabolic and cognitive health in physically inactive individuals.

Author

Melmer, Andreas, Martin‐Niedecken, Anna Lisa, Wehrli, Wanda, Lüchinger, Patrick, Riederer, Yanick, Scott, Sam, Pickles, Jordan, Niedecken, Stephan, Flagmeier, David, Villiger, Stephan, Jurt, Roman, Kind, Nicole, Witthauer, Lilian, Schättin, Alexandra, and Stettler, Christoph

Subjects
*EXERCISE video games, *LDL cholesterol, *DYNAMIC balance (Mechanics), *HEART beat, *BLOOD pressure, *PHYSICAL activity, *EXERCISE intensity
Abstract

Aims: To examine the effects of a home‐based exergame training over 6 weeks on cardio‐metabolic and cognitive health, as well as training adherence, in physically inactive individuals. Materials and Methods: Twenty participants were equipped with an exergame system specifically designed for use at home. Each participant performed at least three weekly exercise sessions at ≥80% of their individual maximum heart rate, over 6 weeks. Exercise duration increased biweekly until 75 min of vigorous exercise were performed in Weeks 5 and 6. Maximum oxygen uptake (VO2max), cardio‐metabolic profiling, and neuro‐cognitive tests were performed at baseline and study end. Additionally, training adherence was assessed via training diaries. Results: After 6 weeks of home‐based exergaming, VO2max increased significantly, while there was a significant decrease in heart rate (resting and maximum), blood pressure (systolic, diastolic and mean), and low‐density lipoprotein cholesterol. Dynamic balance and reaction time improved after 6 weeks of exergaming. Training adherence was 88.4%. Conclusions: Home‐based exergaming induced a clinically relevant increase in VO2max, a determinant of cardiovascular health, accompanied by further improvements in cardiovascular, metabolic and neuro‐cognitive parameters. Exergaming may, therefore, offer an innovative approach to increasing regular physical activity, improving metabolic risk profile, and preventing chronic diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Performance of the Dexcom G6 Continuous Glucose Monitoring System During Cardiac Surgery Using Hypothermic Extracorporeal Circulation

Author

Herzig, David, Vettoretti, Martina, Guensch, Dominik P, Melmer, Andreas, Schürch, Daniel, Roos, Jonathan, Goerg, Arna M C, Krutkyte, Gabija, Cecchini, Luca, Facchinetti, Andrea, Vogt, Andreas P, and Bally, Lia

Subjects
Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, Internal Medicine, 610 Medizin und Gesundheit
Abstract

OBJECTIVEContinuous glucose monitoring (CGM) may be challenged by extreme conditions during cardiac surgery using hypothermic extracorporeal circulation (ECC).RESEARCH DESIGN AND METHODSWe evaluated the Dexcom G6 sensor in 16 subjects undergoing cardiac surgery with hypothermic ECC, of whom 11 received deep hypothermic circulatory arrest (DHCA). Arterial blood glucose, quantified by the Accu-Chek Inform II meter, served as reference.RESULTSIntrasurgery mean absolute relative difference (MARD) of 256 paired CGM/reference values was 23.8%. MARD was 29.1% during ECC (154 pairs) and 41.6% immediately after DHCA (10 pairs), with a negative bias (signed relative difference: −13.7%, −26.6%, and −41.6%). During surgery, 86.3% pairs were in Clarke error grid zones A or B and 41.0% of sensor readings fulfilled the International Organization for Standardization (ISO) 15197:2013 norm. Postsurgery, MARD was 15.0%.CONCLUSIONSCardiac surgery using hypothermic ECC challenges the accuracy of the Dexcom G6 CGM although recovery appears to occur thereafter.

Published
2023

10. Randomized, double-blind, placebo-controlled crossover trial of once daily empagliflozin 25 mg for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass

Author

Ferreira, Antonio, primary, Schönenberger, Katja, additional, Potoczna, Natascha, additional, Vogt, Andreas, additional, Gerber, Philipp, additional, Zehetner, Jörg, additional, Giachino, Daniel, additional, Nett, Philipp, additional, Gawinecka, Joanna, additional, Cossu, Luca, additional, Fuster, Daniel, additional, Dalla Man, Chiara, additional, Facchinetti, Andrea, additional, Melmer, Andreas, additional, Nakas, Christos T, additional, Hepprich, Matthias, additional, Donath, Marc, additional, Herzig, David, additional, and Bally, Lia, additional

Published
2023
Full Text
View/download PDF

11. Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Author

Ferreira, Antonio, Schönenberger, Katja A; https://orcid.org/0000-0002-2122-4746, Potoczna, Natascha, Vogt, Andreas, Gerber, Philipp A, Zehetner, Jörg, Giachino, Daniel, Nett, Philipp, Gawinecka, Joanna, Cossu, Luca; https://orcid.org/0000-0002-8804-0722, Fuster, Daniel G, Dalla Man, Chiara, Facchinetti, Andrea, Melmer, Andreas, Nakas, Christos T, Hepprich, Matthias, Donath, Marc Y, Herzig, David, Bally, Lia; https://orcid.org/0000-0003-1993-7672, Ferreira, Antonio, Schönenberger, Katja A; https://orcid.org/0000-0002-2122-4746, Potoczna, Natascha, Vogt, Andreas, Gerber, Philipp A, Zehetner, Jörg, Giachino, Daniel, Nett, Philipp, Gawinecka, Joanna, Cossu, Luca; https://orcid.org/0000-0002-8804-0722, Fuster, Daniel G, Dalla Man, Chiara, Facchinetti, Andrea, Melmer, Andreas, Nakas, Christos T, Hepprich, Matthias, Donath, Marc Y, Herzig, David, and Bally, Lia; https://orcid.org/0000-0003-1993-7672

Abstract

Aims: To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB). Methods: Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed-meal tolerance test (MMTT). Outcomes of the outpatient period were assessed using continuous glucose monitoring (CGM) and an event-tracking app. Results: The amplitude of glucose excursion during the MMTT was 8.1 ± 2.4 mmol/L with empagliflozin versus 8.1 ± 2.6 mmol/L with placebo (mean ± standard deviation, P = 0.807). CGM-based mean amplitude of glucose excursion during the 20-day period was lower with empagliflozin than placebo (4.8 ± 1.3 vs. 5.2 ± 1.6. P = 0.028). Empagliflozin reduced the time spent with CGM values >10.0 mmol/L (3.8 ± 3.5% vs. 4.7 ± 3.8%, P = 0.009), but not the time spent with CGM values <3.0 mmol/L (1.7 ± 1.6% vs. 1.5 ± 1.5%, P = 0.457). No significant difference was observed in the quantity and quality of recorded symptoms. Eleven adverse events occurred with empagliflozin (three drug-related) and six with placebo. Conclusions: Empagliflozin 25 mg reduces glucose excursions but not hypoglycemia in individuals with PBH.

Published
2023

12. Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) system during cardiac surgery using hypothermic extracorporeal circulation

Author

Herzig, David, primary, Vettoretti, Martina, primary, P. Guensch, Dominik, primary, Melmer, Andreas, primary, Schürch, Daniel, primary, Roos, Jonathan, primary, Goerg, Arna M. C., primary, Krutkyte, Gabija, primary, Cecchini, Luca, primary, Facchinetti, Andrea, primary, Vogt, Andreas P, primary, and Bally, Lia, primary

Published
2023
Full Text
View/download PDF

14. Analysis of diabetes attitudes, wishes and needs in Switzerland, the Swiss DAWN2™ Study

Author

Kuratli, Oliver Andreas, Gross, Carolina, Laimer, Markus, and Melmer, Andreas

Subjects
610 Medicine & health, General Medicine
Abstract

AIMS OF THE STUDY: Swiss DAWN2™ aimed to evaluate the difficulties and unmet needs of individuals with diabetes and stakeholders, based on the assessments of diabetes care and self-management: the individual burden of disease, the perception of the quality of medical care, and the treatment satisfaction of individuals with diabetes living in the Canton of Bern. The results of the Swiss cohort were analysed and compared with the global DAWN2™ results. METHODS: 239 adult individuals with diabetes were enrolled in a cross-sectional study at the Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism at the University Hospital of Bern between 2015 and 2017. The participants completed validated online questionnaires regarding health-related quality of life (EQ-5D-3L) and emotional distress (PAID-5), diabetes self-care activities (SDSCA-6), treatment satisfaction (PACIC-DSF), and health-related wellbeing (WHO-5). Eligibility criteria were as follows: participants were aged >18 years, had a diagnosis of diabetes type 1 or 2 since at least 12 months and gave written informed for the participation in the present study. RESULTS: When compared globally, the Swiss cohort reported a higher quality of life (77.28 ± 16.73 vs. 69.3 ± 17.9 EQ-5D-3L score, p 7% correlated to emotional distress (PAID-5, 26.08 ± 23.37 vs. 18.80 ± 17.49, p = 0.024), unfavourable eating habits (4.28 ± 2.22 vs. 4.99 ± 2.15, p = 0.034) and decreased physical activity (3.95 ± 2.16 vs. 4.72 ± 1.92, p = 0.014). Sleeping problems were most commonly reported (35.6%). In total, 28.8% of respondents completed diabetes-related educational programs. CONCLUSION: In global comparison, Swiss DAWN2™ showed a lower burden of disease and yet a higher level of treatment satisfaction in patients who were treated in Switzerland. Further studies are required to assess the quality of diabetes treatment and unmet needs in patients treated outside of a tertiary care center.

Published
2023
Full Text
View/download PDF

16. Type 1 diabetes mellitus and SARS-CoV-2 in pediatric and adult patients - Data from the DPV network

Author

Büttner, Bastian Raphael, Tittel, Sascha René, Kamrath, Clemens, Karges, Beate, Köstner, Katharina, Melmer, Andreas, Müller-Roßberg, Elke, Richter, Friederike, Rohrer, Tilman R, and Holl, Reinhard W

Subjects
Adult, Glycated Hemoglobin, Diabetes Mellitus, Type 1, SARS-CoV-2, Endocrinology, Diabetes and Metabolism, Humans, COVID-19, 610 Medicine & health, Prospective Studies, Child, Diabetic Ketoacidosis
Abstract

Journal of diabetes 14(11), 758-766 (2022). doi:10.1111/1753-0407.13332, Published by Wiley-Blackwell, Oxford [u.a.]

Published
2022

17. Bariatric surgery prevents carotid wall thickness progression

Author

Lunger, Lukas, primary, Melmer, Andreas, additional, Sturm, Wolfgang, additional, Lamina, Claudia, additional, Tschoner, Alexander, additional, Engl, Julia, additional, Hönlinger, Armin, additional, Engler, Clemens, additional, Willeit, Peter, additional, Kiechl, Stefan, additional, Willeit, Johann, additional, Öfner, Dietmar, additional, Wykypiel, Heinz, additional, Laimer, Markus, additional, Tilg, Herbert, additional, and Ebenbichler, Christoph, additional

Published
2022
Full Text
View/download PDF

18. Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass

Author

Ferreira, Antonio, primary, Emara, Ahmed Fahiem Abdelsalam, additional, Herzig, David, additional, Melmer, Andreas, additional, Vogt, Andreas P, additional, Nakas, Christos T, additional, Facchinetti, Andrea, additional, Dalla Man, Chiara, additional, and Bally, Lia, additional

Published
2022
Full Text
View/download PDF

19. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium

Author

Melmer, Andreas, Fineder, Linda, Lamina, Claudia, Kollerits, Barbara, Dieplinger, Benjamin, Braicu, Ioana, Sehouli, Jalid, Cadron, Isabelle, Vergote, Ignace, Mahner, Sven, Zeimet, Alain G., Castillo-Tong, Dan Cacsire, Ebenbichler, Christoph F., Zeillinger, Robert, and Dieplinger, Hans

Published
2013
Full Text
View/download PDF

22. Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease

Author

Pitkänen, Niina, primary, Finkenstedt, Armin, additional, Lamina, Claudia, additional, Juonala, Markus, additional, Kähönen, Mika, additional, Mäkelä, Kari-Matti, additional, Dieplinger, Benjamin, additional, Viveiros, Andre, additional, Melmer, Andreas, additional, Leitner, Isabella, additional, Kedenko, Ludmilla, additional, Seppälä, Ilkka, additional, Viikari, Jorma S.A., additional, Mueller, Thomas, additional, Kronenberg, Florian, additional, Paulweber, Bernhard, additional, Lehtimäki, Terho, additional, Zoller, Heinz, additional, Raitakari, Olli T., additional, and Dieplinger, Hans, additional

Published
2021
Full Text
View/download PDF

29. Closed-loop-Systeme – Update 2020

Author

Melmer, Andreas, primary, Tripyla, Afroditi, additional, Herzig, David, additional, Laimer, Markus, additional, Stettler, Christoph, additional, and Bally, Lia, additional

Published
2020
Full Text
View/download PDF

30. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry

Author

Sandig, Dirk, primary, Grimsmann, Julia, additional, Reinauer, Christina, additional, Melmer, Andreas, additional, Zimny, Stefan, additional, Müller-Korbsch, Michael, additional, Forestier, Nicole, additional, Zeyfang, Andrej, additional, Bramlage, Peter, additional, Danne, Thomas, additional, Meissner, Thomas, additional, and Holl, Reinhard W., additional

Published
2020
Full Text
View/download PDF

31. A Single Load of Fructose Attenuates the Risk of Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes on Ultra-Long-Acting Basal Insulin: A Randomized, Open-Label, Crossover Proof-of-Principle Study

Author

Kosinski, Christophe, primary, Herzig, David, additional, Laesser, Céline Isabelle, additional, Nakas, Christos T., additional, Melmer, Andreas, additional, Vogt, Andreas, additional, Vogt, Bruno, additional, Laimer, Markus, additional, Bally, Lia, additional, and Stettler, Christoph, additional

Published
2020
Full Text
View/download PDF

33. Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease.

Author

Pitkänen, Niina, Finkenstedt, Armin, Lamina, Claudia, Juonala, Markus, Kähönen, Mika, Mäkelä, Kari-Matti, Dieplinger, Benjamin, Viveiros, Andre, Melmer, Andreas, Leitner, Isabella, Kedenko, Ludmilla, Seppälä, Ilkka, Viikari, Jorma S.A., Mueller, Thomas, Kronenberg, Florian, Paulweber, Bernhard, Lehtimäki, Terho, Zoller, Heinz, Raitakari, Olli T., and Dieplinger, Hans

Subjects
NON-alcoholic fatty liver disease, TYPE 2 diabetes
Abstract

In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD. Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up. Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23–1.54] per 10 mg/L increase, p<0.0001). Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Letter of reply to 'Breaking a feedback loop: A reassessment of an investigator‐initiated OS‐AID study' by Braune et al.

Author

Künzler, Juri, Laimer, Markus, and Melmer, Andreas

Subjects
INSULIN therapy, ARTIFICIAL pancreases
Abstract

This document is a letter of reply to a study titled "Breaking a feedback loop: A reassessment of an investigator-initiated OS-AID study" by Braune et al. The authors of the letter aim to provide perspective on their own study, which compared the technical reliability and insulin dosing of a 'do-it-yourself artificial pancreas' (DIYAPS) with a commercial hybrid closed-loop system. They clarify that their study did not determine the adequacy of the suggested insulin doses but rather showed that both algorithms adjusted insulin doses in a similar manner. The authors emphasize the importance of recognizing the limitations and challenges of DIYAPS, such as glucose sensor inaccuracy and device handling, and hope that their study encourages patients and physicians to critically evaluate the use of DIYAPS. [Extracted from the article]

Published
2024
Full Text
View/download PDF

35. Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study

Author

Melmer, Andreas, Kempf, Patrick, Lunger, Lukas, Pieber, Thomas R, Mader, Julia K, Stettler, Christoph, Tilg, Herbert, Ebenbichler, Christoph F, and Laimer, Markus

Subjects
610 Medicine & health
Abstract

We investigated the short-term effects of dapagliflozin as adjunct to insulin on insulin sensitivity, postprandial glucose excursions and ketone body production in type 1 diabetes mellitus (T1DM). A total of seven male patients completed the randomized, double-blind, placebo-controlled cross-over trial, receiving 10 mg of dapagliflozin daily for 3 days, followed by placebo, or the reverse. At Day 3, hyperinsulinaemic, euglycaemic clamps and oral glucose tolerance test clamps with repeated blood sampling were performed. Required glucose infusion and blood glucose excursions did not differ significantly between dapagliflozin treatment and placebo (P = 0.491; P = 0.342). Prior to oral glucose, total ketone bodies showed a higher trend following dapagliflozin treatment (P = 0.051). Following oral glucose, total ketone bodies decreased while concentrations of total GLP-1 were higher following dapagliflozin (P = 0.009). Non-esterified free fatty acids did not differ between dapagliflozin treatment and placebo and ketonuria was absent under both conditions. In T1DM, short-term addition of dapagliflozin to insulin influenced neither postprandial glucose excursions nor insulin sensitivity. Following oral glucose, total ketone bodies decreased in parallel with an increase in GLP-1 concentrations, which were higher under dapagliflozin treatment as compared with placebo.

Published
2018
Full Text
View/download PDF

40. Short‐term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo‐controlled, double blind, cross‐over pilot study

Author

Melmer, Andreas, primary, Kempf, Patrick, additional, Lunger, Lukas, additional, Pieber, Thomas R., additional, Mader, Julia K., additional, Stettler, Christoph, additional, Tilg, Herbert, additional, Ebenbichler, Christoph F., additional, and Laimer, Markus, additional

Published
2018
Full Text
View/download PDF

42. Prescription of oral antidiabetic drugs in Tyrol – Data from the Tyrol diabetes registry 2012–2015

Author

Lunger, Lukas, primary, Melmer, Andreas, additional, Oberaigner, Willi, additional, Leo, Marco, additional, Juchum, Martin, additional, Pölzl, Karin, additional, Gänzer, Johannes, additional, Innerebner, Martha, additional, Eisendle, Egon, additional, Beck, Gertrud, additional, Kathrein, Hermann, additional, Heindl, Bernhard, additional, Schönherr, Hans Robert, additional, Lechleitner, Monika, additional, Tilg, Herbert, additional, and Ebenbichler, Christoph, additional

Published
2016
Full Text
View/download PDF

46. Normobaric Intermittent Hypoxia over 8 Months Does Not Reduce Body Weight and Metabolic Risk Factors - a Randomized, Single Blind, Placebo-Controlled Study in Normobaric Hypoxia and Normobaric Sham Hypoxia

Author

Gatterer, Hannes, primary, Haacke, Sven, additional, Burtscher, Martin, additional, Faulhaber, Martin, additional, Melmer, Andreas, additional, Ebenbichler, Christoph, additional, Strohl, Kingman P., additional, Högel, Josef, additional, and Netzer, Nikolaus C., additional

Published
2015
Full Text
View/download PDF

47. Evaluation of the glycoprotein Afamin in obesity, cardiovascular disease and cancer

Author

Melmer, Andreas and Melmer, Andreas

Abstract

Afamin, ein Glykoprotein und Mitglied der Albumin-Superfamilie, wurde 1994 erstmals beschrieben. Bindungs- und Affinitätsexperimente konnten eine physiologisch relevante Transportfunktion von Afamin für Vitamin E feststellen.In Untersuchungen an transgenen Mäusen, welche humanes Afamin überexprimierten, konnte festgestellt werden, dass sich deren Körperkomposition, deren Blutlipidkonzentrationen als auch deren Nüchtern-Glukosespiegel signifikant im Sinne einer jeweils deutlichen Erhöhung im Vergleich zu gesunden Wild-Typ Mäusen unterschieden, woraufhin die Hypothese aufgestellt wurde, dass Afamin eine Funktion in der Entwicklung des metabolischen Syndroms als auch kardiovaskulärer Erkrankung einnehmen könnte. Afamin wurde daraufhin in drei klinischen, prospektiven, populationsbasierten oder Kohortenstudien gemessen, namentlich der Bruneck Studie, der Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk Studie und der “Kooperative Gesundheitsforschung in der Region Augsburg”. Es konnte in all diesen Studien gezeigt werden, dass ein signifikaner Zusammenhang zwischen (im Vergleich zu gesunder Normalbevölkerung) erhöhten Afamin Plasma-Konzentrationen und der Entwicklung und Prävalenz von Kriterien des metabolischen Syndroms besteht.Die vorliegende Arbeit fasst mehrere Studien zusammen, welche sich dem Zusammenhang zwischen Afamin, der Entwicklung und Prävalenz von Obesitas und assoziierten metabolischen Störungen, kardiovaskulärer Erkrankung als auch Krebserkrankungen im Menschen widmen. Afamin wurde hierzu in zwei weiteren Kohortenstudien, namentlich der “Northwick Park Heart Study II” und der „Ludwigshafen Risk and Cardiovascular Health“ Studie gemessen. Es wurde abermals gezeigt, dass ein starker Zusammenhang zwischen der Höhe der Afamin Plasmakonzentration und dem Vor, The glycoprotein afamin, a member of the albumin-superfamily was discovered in 1994 and identified as a capable transport protein for vitamin E isomers. Due to preliminary findings in transgenic mice overexpressing afamin, which showed a significantly higher proportion of adipose tissue, blood lipids and plasma glucose compared to wild-type litter mates, afamin was presumed to play a possible role in the development of the metabolic syndrome. These findings were previously substantiated and expanded in three large-scale, prospective population-based and cohort studies including the Bruneck, the Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk, Kooperative Gesundheitsforschung in der Region Augsburg study. These studies indicated a pronounced and positive correlation between afamin plasma concentrations and the presence and development of criteria of the metabolic syndrome. In the present study we subsume our work done on the identification of afamin as a possible factor in the development of obesity, metabolic disturbances, cardiovascular disease and cancer. We measured afamin in the Northwick Park Heart Study II, and Ludwigshafen Risk and Cardiovascular Health study to identify a possible association between afamin and criteria of the metabolic syndrome and cardiovascular disease. All of these studies showed a highly significant correlation between elevated afamin plasma concentrations and the prevalence of criteria of the metabolic syndrome and type 2 diabetes mellitus. The association between cardiovascular disease, gastric cancer and afamin was present but less obvious.By prospectively investigating afamin plasma concentration in 40 patients undergoing bariatric surgery, we were able to identify an association between afamin plasma concentrations and pronounced weight loss in a clinical prospective design. It was found that the decline in total body adipose tissue and visceral adi, by Andreas Melmer, Abweichender Titel laut Übersetzung der Verfasserin/des Verfassers, Enth. u.a. 5 Veröff. d. Verf. aus den Jahren 2012 - 2013 . - Zsfassung in dt. Sprache, Innsbruck, Med. Univ., Diss., 2014

Published
2014

48. Plasma Concentrations of Afamin Are Associated With the Prevalence and Development of Metabolic Syndrome

Author

Kronenberg, Florian, primary, Kollerits, Barbara, additional, Kiechl, Stefan, additional, Lamina, Claudia, additional, Kedenko, Lyudmyla, additional, Meisinger, Christa, additional, Willeit, Johann, additional, Huth, Cornelia, additional, Wietzorrek, Georg, additional, Altmann, Maria E., additional, Thorand, Barbara, additional, Melmer, Andreas, additional, Dähnhardt, Doreen, additional, Santer, Peter, additional, Rathmann, Wolfgang, additional, Paulweber, Bernhard, additional, Koenig, Wolfgang, additional, Peters, Annette, additional, Adham, Ibrahim M., additional, and Dieplinger, Hans, additional

Published
2014
Full Text
View/download PDF

49. Serum prolactin in advanced chronic liver disease

Author

Ress, Claudia, primary, Maeser, Pirmin, additional, Tschoner, Alexander, additional, Loacker, Lorin, additional, Salzmann, Karin, additional, Staudacher, Gabriele, additional, Melmer, Andreas, additional, Zoller, Heinz, additional, Vogel, Wolfgang, additional, Griesmacher, Andrea, additional, Tilg, Herbert, additional, Graziadei, Ivo, additional, and Kaser, Susanne, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results